Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children

New England Journal of Medicine

Volumn 366, Issue 25, 2012, Pages 2380-2389

  Violari, Avy ^a   Paed, F C ^s   Lindsey, Jane C ^e   Hughes, Michael D ^e   Mujuru, Hilda A ^f   Barlow Mosha, Linda ^g   Kamthunzi, Portia ^h   Chi, Benjamin H ⁱ   Cotton, Mark F ^c   Moultrie, Harry ^b   Khadse, Sandhya ^j   Schimana, Werner ^k   Bobat, Raziya ^d   Purdue, Lynette ^l   Eshleman, Susan H ^o   Abrams, Elaine J ^p   Millar, Linda ^q   Petzold, Elizabeth ^m   Mofenson, Lynne M ⁿ   Jean Philippe, Patrick ^l   Palumbo, Paul ^r   more..

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF JOHANNESBURG   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^g MAKERERE UNIVERSITY   (Uganda)

^h UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

ⁱ CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^j Sassoon General Hospital   (India)

^k DUKE UNIVERSITY   (United States)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^m SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

ⁿ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p Frontier Science and Technology Research Foundation ^*  (United States)

^q FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^r DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^s NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; BODY HEIGHT; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; INFECTION PREVENTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 84862518618     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1113249     Document Type: Article

References (16)

1. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010;363:1510-20.
2. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010;363:1499-509.
3. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach - 2010 revision. Geneva: World Health Organization Technical Reference Group, 2010.
4. Babiker A, Castro HG, Compagnucci A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomized phase 2/3 trial. Lancet Infect Dis 2011;11:273-83.
5. Palumbo P, Wu H, Chadwick E, et al. Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection. J Infect Dis 2007;196:23-9. (Pubitemid 46982733)
6. Luzuriaga K, Wu H, McManus M, et al. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol 1999;73:362-7. (Pubitemid 28565379)
7. Mulenga V, Cook A, Walker AS, et al. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. Clin Infect Dis 2010;51:1081-9.
8. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011;305:1327-35.
9. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 2011;108:9202-7.
10. Hunt GM, Coovadia A, Abrams EJ, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 2011;25:1461-9.
11. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIVinfected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010;304:1082-90.
12. Nachman SA, Lindsey JC, Pelton S, et al. Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. Arch Pediatr Adolesc Med 2002;156:497-503. (Pubitemid 34492584)
13. Dreimane D, Nielsen K, Deveikis A, Bryson YJ, Geffner ME. Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2001;20:315-6. (Pubitemid 32240275)
14. Buchacz K, Cervia JS, Lindsey JC, et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics 2001;108(4):E72.
15. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009;23:661-72.
16. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-44.